Abstract 16617: Is the Benefit Risk Ratio for Patient Treated With Pulmonary Vein Isolation Cryablation for Recurrent AF in an Older Population Still Favorable?
Is the benefit/risk ratio for patient treated with PVI Cryablation for recurrent AF in an older population (age 75 or more) still favorable?
Introduction: Pulmonary vein cryoablation (PVC) is an approved therapy in symptomatic, recurrent atrial fibrillation (AF). Efficacy, and safety of PVC in the older patients is unknown. We evaluated whether procedure time, acute complication and AF recurrence differed according to the patient’s age.
Methods: From April 2012, 1327 patients (73% male, 59 ± 11 years; mean left atrial diameter 41±6 mm) underwent PVC. Data were collected prospectively in the framework of the One Shot TO Pulmonary vein isolation (1STOP) ClinicalService® project. All patients were divided in three age groups ((<65, 65 to 74, ≥ 75 years).
Results: 858 patients were < 60 years, while 61 patients were ≥ 75 years. The prevalence of co-morbidities and chads2 score risk increased with age. The 3 groups showed comparable procedure and fluoroscopy times respectively 118±47 min and 30±14 min. The acute success rate and the rate of acute procedural complications were similar among the 3 groups. The 12month freedom of AF recurrence probability was 74% in the younger patient as compared with 70% in the middle age group and with 66% in the older patients (p=NS) as shown in fig 1.
Conclusions: In our experience only the 4% of patients treated with PV cryoablation were ≥ 75 years. PV cryoablation was safe and effective regardless of the age of patients.
Author Disclosures: L. Padeletti: None. R. Verlato: None. G. Arena: None. S. Iacopino: None. A. Curnis: None. M. Lunati: None. G. Molon: None. S. Porcellini: None. L. Sciarra: None. C. Tondo: None.
- © 2016 by American Heart Association, Inc.